RecruitingMajor Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Eligible age

18–65 yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.

Sponsor: Axsome Therapeutics, Inc.

You may qualify if…

✓ Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT
✓ Excessive daytime sleepiness symptoms
✓ Able to comply with study procedures
✓ Male or female, aged 18 to 65 years inclusive

You may not qualify if…

✕ Any clinically significant medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms
✕ Unable to comply with study procedures
✕ Medically inappropriate for study participation in the opinion of the investigator